p53-Independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: Suppression of apoptosis during the transition from preneoplasia to carcinoma

Cancer Research

Volumn 56, Issue 13, 1996, Pages 2998-3003

  Shibata, Masa Aki ^a   Maroulakou, Ioanna G ^a   Jorcyk, Cheryl L ^a   Gold, Lyn G ^a   Ward, Jerrold M ^a   Green, Jeffrey E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; DNA; PROTEIN P21; PROTEIN P53; STEROID BINDING PROTEIN; VIRUS LARGE T ANTIGEN;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; BREAST HYPERPLASIA; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DIAGNOSIS; FEMALE; GENOTYPE; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN VIRUS 40; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; TRANSGENIC MOUSE; TUMOR GROWTH;

ANDROGEN-BINDING PROTEIN; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE PROGRESSION; FEMALE; GENES, P53; GENOTYPE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PRECANCEROUS CONDITIONS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; TUMOR SUPPRESSOR PROTEIN P53; UTEROGLOBIN;

EID: 0030008732     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Parker, M G. R., White, H., Hurst, M., Needham, M., and Tilly, R Prostatic steroid-binding protein Isolation and characterization of C3 genes. J. Biol Chem, 258: 12-15, 1983
2. Maroulakou, I. G., Anver, M., Garrett, L, and Green, J E. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl Acad. Sci. USA, 91: 11236-11240, 1994.
3. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis Cell, 61: 759-767, 1990.
4. Dyson, N., Buchkovich, K., Whyte, P., and Harlow, E. The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. Cell, 58: 249-255, 1989
5. Mietz, J. A., Unger, T., Huibregtse, J M., and Howley, P. M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO. J, 11: 5013-5020, 1992.
6. Levine, A. J. The tumor suppressor genes. Annu. Rev Biochem, 62: 623-651, 1993
7. Greenblatt, M S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene clues to cancer ecology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
8. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62. 671-680, 1990.
9. Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E, Romano, J. W., and Ullrich, S J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl. Acad. Sci. USA, 87: 6166-6170, 1990.
10. Diller, L., Kassel, J., Nelson, C E, Gryka, M. A., Litwak, G., Gebhardt, M, Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B., and Friend, S. H. p53 function as a cell cycle control protein in osteosarcoma. Mol. Cell. Biol, 10. 5772-5781, 1990.
11. 1 phase. Proc. Natl. Acad. Sci. USA, 89: 9210-9214, 1992.
12. Kasatan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B, and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
13. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992
14. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B, Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W, and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
15. Xiong, Y., Zhang, H., and Beach, D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev., 7: 2277-2284, 1993.
16. Zhang, H., Xiong, Y., and Beach, D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol. Cell, 4: 897-906, 1993.
17. Ramqvist, T., Magnusson, K. P., Wang, Y, Szekely, L. Klein, G., and Wiman, K. G. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant: p53. Oncogene, 8: 1495-1500, 1993.
18. Yonishi-Rouach, E. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
19. Kerr, J. F. R., Wyllie, A. H., and Currie, A. R. Apoptosis. A basic biological phenomenon with wide ranging implications in tissue kinetics. Br. J Cancer, 26. 239-257, 1972.
20. Li, M., Hu, J., Heermeier, K.. Hennighausen, L., and Furth, P. A. Expression of a viral oncoprotein during mammary gland development alters cell fate and function: induction of p53-independent apoptosis is followed by impaired milk protein production in surviving cells. Cell Growth & Differ., 7: 3-11, 1996.
21. Williams, G. T. Programed cell death: apoptosis and oncogenesis. Cell, 65: 1097-1098, 1991.
22. Jacks, T. Remington, L, Williams, B. O., Schmitt, E. M, Halachmi, S., Bronson, R T, and Weinberg, R A Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7, 1994.
23. Shi, S-R., Key, M. E., and Kalra, K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem. Cytochem., 59: 741-748, 1991
24. Fox, C. H, and Cottler-Fox, M. In situ hybridization in HIV research. Microsc. Res. Tech., 25: 78-84, 1993.
25. Orita, M., Youichi, S., Sekiya, T, and Hayashi, K. Rapid sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5: 874-879, 1989.
26. Hartmann, A., Blaszyk, H., McGovern, R. M., Schroeder, J. J.. Cunningham, J, De Vries. E M G., Kovach, J. S., and Sommer, S. S. p53 gene mutations inside and outside of exons 5-8. the patterns differ in breast and other cancers. Oncogene, 10: 681-688, 1995.
27. Ruggen, B., Caamano, J., Goodrow, T., DiRado, M, Bianchi, D., Trono, D, Conti, C J, and Klein-Szanto, A J. P Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res, 51: 6615-6621, 1991.
28. Foley, J., Ton, T., Maronpot, R., Butterworth, B., and Goldsworthy, T L. Comparison of proliferating cell nuclear antigen to tritiated thymidine as a marker of proliferating hepatocytes in rats Environ. Health Perspect, 101 (Suppl 5). 199-206, 1993.
29. Oren, M, Maltzman, W., and Levine, A. J Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol. Cell. Biol., 1: 101-110, 1981.
30. Reich, N. C., Oren, M., and Levine, A J. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol, 3: 2143-2150, 1983.
31. Raff, M. C. Social controls on cell survival and cell death. Nature (Lond.), 356-398-400, 1992
32. Symonds, H. Krall, L., Remington, L, Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78: 703-711, 1994
33. van Dierendonck, J. H., Wysman, J. H., Keijzer, R., van de Velde, C. J. H, and Cornelisse, C. J. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Am. J. Pathol., 138: 1165-1172, 1991.
34. Baserga, R. Growth regulation of the PCNA gene. J. Cell Sci, 98. 433-436, 1991.
35. Shivakumar, C. V., Brown, D R., Deb, S., and Deb, S. P. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter Mol. Cell. Biol., 15: 6785-6793, 1995.
36. Harper, J. W., Adami, G. R., Wei, N, Keyomarsi, K., and Elledge, S. J. The p21 cdk-interacting protien Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
37. Chen, J., Jackson, P. K., Kirschner, M. W., and Dutta, A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature (Lond.), 374. 386-388, 1995
38. Michieli, P, Chedid, M, Lin, D, Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF3/CIP1 by a p53-independent pathway. Cancer Res., 54 3391-3395, 1994.
39. Zhang, W, Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travali, S., Deisseroth, A, B., and Mercer, W. E. p53-Independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/ macrophage differentiation. Cancer Res., 55: 668-674, 1995.
40. Halevy, O., Michalovitz, D, and Oren, M. Different tumor-derived p53 mutants exhibit distinct biological activities Science (Washington), 250: 113-116, 1990.